CEL-SCI prices $5M offering of common stock at $2.00 per share

CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced the pricing of an offering of 2,490,000 shares of its common stock to a single investor at an offering price of $2.00 per share, for gross proceeds of approximately $5 million, before deducting underwriting discounts and offering expenses. All of the shares of common stock are being offered by the Company. The offering is expected to close on November 20, 2023, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering to fund the continued development of Multikine,* for general corporate purposes, and working capital. ThinkEquity is acting as sole book-running manager for the offering.